GHK, the peptide backbone of GHK-Cu, occurs naturally in human plasma, saliva, and urine, and its concentration declines with age. It was first isolated from human plasma in the early 1970s, and the research that followed was largely concerned with its role in tissue repair: how the body signals and coordinates wound healing, and why that signalling appears to weaken as people get older. The copper-bound form, GHK-Cu, is the biologically active complex studied in most of this literature.

A substantial review of this literature describes GHK-Cu as stimulating wound healing across numerous animal models and in humans, accelerating replicative activity in fibroblasts, and playing a coordinating role across the phases of tissue repair. This is genuinely foundational biology, not a marketing narrative built after the fact.

It's tempting to think of scar improvement as simply "more collagen," but the research points to something more specific: scar quality depends on how collagen is organised, not just how much of it is present. Freshly healed tissue is initially rich in type III collagen laid down in a disorganised pattern. Over the following months, that immature matrix is meant to be gradually broken down and replaced with more organised type I collagen, a process called maturation. Whether that remodelling happens well is a large part of what determines whether a scar ends up flat and low-visibility, or raised, thickened, and more noticeable.

This is where GHK-Cu's documented mechanism is genuinely relevant. Research has established that GHK-Cu stimulates both collagen synthesis and the activity of matrix metalloproteinases (MMPs), the enzymes responsible for breaking down existing matrix. That combination, building new material while also clearing and reorganising the old, is what remodelling actually requires. GHK-Cu is also documented to stimulate glycosaminoglycan (GAG) and elastin production, additional components of the dermal matrix that contribute to skin's structure and resilience beyond collagen alone.

This dual synthesis-and-breakdown activity is the same underlying mechanism discussed in the article on copper uglies, where the same remodelling activity is discussed in the context of a theorised temporary cosmetic effect rather than scarring specifically.

It's worth being precise about the context most of this research was conducted in, because it's not the same context as a facial cosmetic serum. A significant proportion of the strongest wound-healing evidence for GHK-Cu comes from chronic and clinical wound models, diabetic wounds, radiation-impaired healing, and animal wound models, often using higher concentrations, different delivery methods, or formulations designed for actual wound management rather than cosmetic use on intact or already-healed skin.

Because so much of the underlying research involves actual wound care, it's worth being direct about scope. 1% GHK-Cu Face and Skin Serum is a cosmetic product, not a wound-care product or a medical device, and it is not intended for use on open or active wounds, fresh post-surgical incisions, or any injury that would otherwise require clinical wound management. Active wounds, signs of infection, or anything that isn't fully closed and healed need appropriate medical attention, not a cosmetic serum applied on the assumption that the wound-healing literature transfers directly.

Where a cosmetic serum reasonably fits is on skin that has already closed and healed, existing scars from past injuries, surgery, or acne, where the interest is in supporting the skin's own ongoing remodelling and general texture and appearance, not in managing an active wound.

For a fully closed and healed scar, patch testing on a small area first is sensible before wider application, the same as introducing any new active. Scar tissue can sometimes be more sensitive than surrounding skin, and starting cautiously makes it easier to identify any reaction early.

Timing matters too. Scar tissue continues remodelling naturally for months after a wound closes, and a scar that's very recent may still be in the middle of that natural process regardless of what's applied to it. Anyone with a history of keloid or hypertrophic scarring, where the skin's own remodelling process tends to overshoot and produce raised, thickened scar tissue, should be particularly cautious about introducing any new active to healing or recently healed skin without input from a dermatologist, since the interaction between that predisposition and any additional stimulation of tissue remodelling isn't well characterised.

As with any cosmetic active, consistency matters more than any single application, and meaningful change in scar appearance, if it occurs, is a matter of months rather than days or weeks, consistent with how long skin remodelling genuinely takes.

These papers establish GHK-Cu's documented mechanism in tissue remodelling and wound healing, largely in wound and clinical models. They do not constitute clinical trial evidence that a cosmetic facial serum measurably improves the appearance of existing scars in humans; that specific claim has a thinner evidence base than the underlying mechanism.

This article is provided for educational purposes. GHK-Cu is a cosmetic formulation and is not intended to diagnose, treat, cure, or prevent any condition, and is not a substitute for medical wound care. Do not apply to open wounds, active injuries, or unhealed surgical sites. If you have concerns about a wound, scar, or skin condition, consult a qualified healthcare professional.

AmpleLab.